Andrea Corona MapLight reports mixed results in Schizophrenia trial In their Phase 2 ZEPHR trial, MapLights novel oral drug for schizophrenia, the Ml/M4 muscarinic agonist ML-007C-MA, successfully hit its primary endpoint but only for the twice-daily version, not the once-daily dose
and Ipamorelin, a selective growth-hormone secretagogue, for ghrelin/GHS-receptor pathway research
These phospholipids protect the contents from degradation in the digestive tract so they can pass through the hostile environment and enter the bloodstream.19 We can compare a couple of studies to determine the effect on bioavailability that liposomal delivery can impart
Krzem HA skadnik odpowiedzialny za popraw struktury skry, wygadzanie zmarszczek oraz dziaanie liftingujce
TB-500 is a synthetic peptide modeled after thymosin beta-4, tested for its own role in tissue repair and inflammation